Anatara Lifesciences Ltd (ASX:ANR) is developing an OTC medicine to address factors associated with gastrointestinal (GI) disorders such as irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD): microbiome dysbiosis, inflammation and mucosal damage.
Anatara's CEO, Steve Lydeamore will be presenting to investors at AusBiotech + Invest 2020 on 29th October 2020. Register to attend free for qualified investors.
Anatara Lifesciences (ASX:ANR) is pleased to release to investors a copy of the presentation that Chief Executive Officer, Mr. Steven Lydeamore, will present today at the ASX Small and Mid-Cap Conference 2020, a virtual conference.
Steven Lydeamore, Chief Executive Officer, Anatara Lifesciences (ASX:ANR) will be presenting at the ASX Small and Mid-Cap Conference 2020.
Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, is pleased to announce that is has received a payment of 100M JPY (~A$1.3M) from Kyocera Corporation (Kyocera, TYO:6971)
Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today announced that its CEO Leo Lee, will present at the Finance News Network (FNN) CEO Showcase virtual event on Tuesday 25 August 2020 at 12:55pm (AEST). The event is primarily attended by Australian-based retail investors and advisors.
Anatara Lifesciences (ASX:ANR) today released its Appendix 4E and review of operations for the period ending 30 June 2020.
